Ortho Evra Patch Label Warnings
According to the latest news from the FDA, Ortho and FDA notified healthcare professionals and patients about
changes to the available prescribing information to inform them of the results of two separate epidemiology studies evaluating the risk of developing a serious blood clot in women using Ortho Evra compared to women using a different oral contraceptive.
The first study found that the risk of non-fatal venous thromboembolism (VTE) associated with the use of Ortho
Evra contraceptive patch is similar to the risk associated with the use of oral contraceptive pills containing 35 micrograms of ethinyl estradiol and norgestimate.
